

**Harvard Medical School/Harvard School of Dental Medicine
Format for the Curriculum Vitae**

Date Prepared: July 2010

Name: Jeffrey W. Clark

Office Address: Massachusetts General Hospital Cancer Center
Division of Hematology/Oncology
55 Fruit Street, Professional Office Building, Suite 234
Boston, MA 02114
(617) 643-3415

Work Phone: 617-724-4000

Work Email: jclark@partners.org

Work FAX: (617) 724-3166

Place of Birth: Manila, Philippines

Education

1974	S.B.		Massachusetts Institute of Technology
1978	M.D.		Tufts University School of Medicine

Postdoctoral Training

1971-1974	Undergraduate Research	Biology	MIT, Cambridge, MA
1976	Summer Research	Department of Cardiology	Tufts University School of Medicine, New England Medical Center, Boston, MA
1977	Summer Research	Department of Hematology	Tufts University School of Medicine, New England Medical Center, Boston, MA
1978-1981	Resident	Internal Medicine	New England Deaconess Hospital, Boston, MA
1978-1981	Clinical Fellow	Medicine	Harvard Medical School, Boston, MA
1981-1982	Clinical Fellow	Oncology, Medicine Branch	COP, NCI, NIH, Bethesda, MD
1982-1984	Research Fellow	Environmental Epidemiology Branch	EBP, DCE, NCI, NIH,

Bethesda, MD

1984-1985 Senior Staff Fellow Environmental Epidemiology Branch EBP, DCE, NCI, NIH, Bethesda, MD

Faculty Academic Appointments

1985-1988 Senior Investigator Clinical Research Branch BRMP, DCT, NCI-FCRF, Frederick, MD
1988-1995 Assistant Professor Medicine Brown University Program in Medicine, Providence, RI
1995-2006 Assistant Professor Medicine Harvard Medical School, Boston, MA
2006- Associate Professor Medicine Harvard Medical School, Boston, MA

Appointments at Hospitals/Affiliated Institutions

1985-1988 Senior Investigator Clinical Research Branch BRMP, DCT, NCI-FCRF, Frederick, MD
1988-1995 Staff Physician Division of Medical Oncology Roger Williams Hospital, Providence, RI
1993-1995 Director, Clinical Trials Clinical Trials Program Brown University Cancer Center, Providence, RI
1994-1995 Consulting Staff Division of Medical Oncology Rhode Island Hospital, Providence, RI
1995- Associate Physician Division of Medical Hematology Oncology Massachusetts General Hospital, Boston, MA
1995- Associate Physician Division of Medical Hematology Oncology Brigham and Women's Hospital, Boston, MA
1995- Associate Physician Division of Medical Hematology Oncology Dana-Farber Cancer Institute, Boston, MA

Other Professional Positions

1985 Guest Researcher, Oncology WIA Cancer Institute, Madras, India

Major Administrative Leadership Positions

Local

1995-2004 Director, Medical Oncology GI Program Massachusetts General Hospital, Boston, MA
1995- Medical Director of Clinical Trials MGH Cancer Center MA

1996-	Director, Clinical Trials Core of Dana-Darber/Partners Cancer Care	Massachusetts General Hospital, Boston, MA
2000-	Medical Director, Clinical Trials Infrastructure	Dana Farber Harvard Cancer Center, Boston, MA
2004-2010	Director, Medical Oncology Experimental Therapeutics Program	Massachusetts General Hospital, Boston, MA

Regional

National and International

2000-	Principle Investigator	CALGB Grant, MGH
-------	------------------------	------------------

Committee Service

Local

1996-	Gastrointestinal Oncology Research Committee	Dana-Farber/Harvard Cancer Center (DF/HCC)
1996-	1996-	Member
1996-	Phase I Experimental Therapeutics Group	Dana-Farber/Harvard Cancer Center (DF/HCC)
1996-	1996-	Member
1996-2000	Clinical Operations Committee	Dana-Farber/Harvard Cancer Center (DF/PCC)
1996-2000	1996-2000	Chair
1996-2000	Scientific Review Committee	Dana-Farber/Harvard Cancer Center (DF/HCC)
1996-2000	1996-2000	Member
1998-	Clinical Policy Oversight Committee	Dana-Farber/Harvard Cancer Center (DF/HCC)
1998-	1998-	Member
1998-	Investigational Review Board	Dana-Farber Cancer Institute (DFCI)
1998-	1998-	Member
2000-	Clinical Operations Committee	Dana-Farber/Harvard Cancer Center (DF/HCC)
2000-	2000-	Chair
2002-	Next Generation Order Entry Committee	Dana-Farber/Harvard Cancer Center (DF/PCC)
2002-	2002-	Member
2002-	Panel C	Dana-Farber Cancer Institute (DFCI)
2002-	2002-	Member
2002-	Biostatistics Core Clinical User Committee	Dana-Farber/Harvard Cancer Center (DF/HCC)
2002-	2002-	Chair
2003-2004	Committee for AAHRP Accreditation	Dana-Farber/Harvard Cancer Center (DF/HCC)
2003-2004	2003-2004	Member
2003-	Committee for Electronic Data Capture	Dana-Farber/Harvard Cancer Center (DF/HCC)
2003-	2003-	Member
2003-	IT Support of Clinical Research Taskforce	Dana-Farber/Partners Cancer care (DF/PCC)
2003-	2003-	Member

National and International

1996-2003	Rules Committee	American Society of Clinical Oncology
1996-2003	1996-2003	Member
1999-2007	Gastrointestinal Core Committee	Cancer and Leukemia Group B
1999-	Core Committee in Medical Oncology	American College of Surgical Oncology Group

2000-	1999- Cancer Network Committee	Member National Comprehensive Cancer Network
2004-2006	2000 Scientific Programs Committee 2004-2006	Member American Society of Oncology Member

Professional Societies

1977-	Alpha Omega Alpha 1977-	Member
1983-	American Society of Clinical Oncology 1983-	Member
1988-1995	American Federation for Clinical Research 1988-1995	Member
1990-1995	American Society for Bone and Mineral Research (ASBMR) 1990-1995	Member
1990-	American Association for Cancer Research 1990-	Member

Grant Review Activities

2001-	NCCN Clinical Trial Grants	Committee Member
2008-	AACR-PANCAN Innovative Grants	Reviewer

Editorial Activities

The New England Journal of Medicine
Cancer
Oncologist
Journal of Surgical Oncology
British Journal of Cancer
Clinical Cancer Research

Other Editorial Roles

Honors and Prizes

1979	Outstanding Intern Award	New England Deaconess Hospital	
1980	Hinton Award	New England Deaconess Hospital, Harvard Medical School	Outstanding Physician- Patient Relationships
1996	Partners in Excellence Award	Massachusetts General Hospital, Boston MA	COE Development Program
1999	Kenneth B. Schwartz Compassionate Caregiver	Massachusetts General Hospital, Boston MA	Honorable Mention

2003	Awards Kenneth B. Schwartz Compassionate Caregiver Awards	Massachusetts General Hospital, Boston MA	Honorable Mention
2004	Partners in Excellence Award	Massachusetts General Hospital, Boston MA	DF/PCC Affiliate Network Program
2004	Partners in Excellence Award	Massachusetts General Hospital, Boston MA	DF/HCC ONCPRO Team
2009-2011	Clinical Investigator Team Leadership Award	NCI-ASCO	Clinical Investigator Team Leadership Award

Report of Funded and Unfunded Projects

Funding Information

Past

22XS126A (Clark) 06/23/2003-12/22/2007

Science Applications International Corporation (Role: Principal Investigator)

Correlation studies for protocol P5642, a study of antiangiogenic agent bevacizumab in combination with 5-fluorouracil and external beam radiation.

R21CA099237 (Clark) 09/21/2004-07/31/2008

NIH/NCI A Phase I Study of Antiangiogenic Agent Bevacizumab in Combination 5-Fluorouracil and External Beam Radiation Therapy in Rectal Cancer

Doris Duke Clinical Interfaces Award (Seiden) 12/01/2005-08/31/2008

Role: Co-Investigator Clinical application of molecular imaging to oncology.

This grant funded an intraperitoneal molecular imaging program.

Co-investigator: Human Subjects Research Protections Outreach Project (supplemental funding to P30CA06516 (Benz) The focus of my involvement was to assist in the development of educational materials for human research subjects protection. This has included development of a CD describing clinical trials and the consent process.

Co-investigator: Health Outcomes Research Starter Grant (supplemental funding to P30CA06516 (Benz) My primary role in this project was to serve as advisor to the principal investigator, providing guidance on the design and conduct of the research, as well as on interpretation of the findings.

Current

U01CA62490 (Kufe) 07/15/2008-02/28/2013

NIH/NCI/DFCI/Subaward to MGH (Supko, MGH Site PI)

Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis

Perform Phase I clinical trials of investigational antineoplastic agents

P30CA06516 (Benz) 05/19/2006-11/30/2011

NIH/NCI/DFCI/Subaward to MGH

Dana-Farber/Harvard Cancer Center Grant (DFHCC) Core Grant supporting DFHCC.

P30CA06516 (Benz) 09/01/2009-08/31/2011
 NCI-ASCO Clinical Investigator Team Leadership Supplemental Award
 NIH/NCI/DFCI/Subaward to MGH
 Dana-Farber/Harvard Cancer Center Grant (DFHCC)

3P30CA006516-46S6 (Jomol, Clark) 09/01/2009 – 08/31/2011 ADOPTION of New Technologies for Remote Data Capture & Protocol Authoring.

Current Unfunded Projects

Report of Local Teaching and Training

Teaching of Students in Courses

1995-	Reviewing patients' medical care medical students	Massachusetts General Hospital 28 hours/year
1995-	Education of residents and medical students in outpatient GI Oncology Clinic medical students	Massachusetts General Hospital 80 hours/year
1995-	New oncology patient conference medical students	Massachusetts General Hospital 50 hours/year
1995-	Noontime chief's oncology conference medical students	Massachusetts General Hospital 50hours/year

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

1995-	Reviewing patients' medical care medical students and residents	Massachusetts General Hospital
1995-	Education of residents and medical students in outpatient GI Oncology Clinic medical students and residents	Massachusetts General Hospital 28 hours/year
1995-	New oncology patient conference medical students and residents, oncology fellows	Massachusetts General Hospital 80 hours/year
1995-	Noontime chief's oncology conference medical students and residents, oncology fellows	Massachusetts General Hospital 50 hours/year
1996-	Internal Medicine Residency Training Program	Massachusetts General Hospital 25 hours/year
2001-	Medical House Staff Residents' Report colorectal cancer medical students and residents, oncology fellows	Massachusetts General Hospital 4 hours/year
2002	Chronic myelogenous leukemia residents	Massachusetts General Hospital 4 hours/year

2003- gastric cancer/ Massachusetts General Hospital
4 hours/year

Clinical Supervisory and Training Responsibilities

1995 Ongoing education of medical oncology fellows 100 hours/year
DF/PCC

Laboratory and Other Research Supervisory and Training Responsibilities

Formally Supervised Trainees

Junji Kato, 1989-1991
MD
David Ryan 1996-1999
MD
Bernardo 2005-2007
Goulart MD

Formal Teaching of Peers (e.g., CME and other continuing education courses)

1994 Therapy of stage IV disease Lecture
Comprehensive Management of Breast Cancer and Breast/ Newport, RI
Medical Education Collaborative

2002 Pancreatic cancer Lecture
Harvard Med School

2003 Novel Agents in Cancer Therapy Lecture
Update on Cancer Treatment Harvard Med School

2006	Colorectal Cancer: Update on Treatment	Lecture Harvard Med School
2007	Colorectal Cancer: Update on Treatment	Lecture Harvard Med School
2010-	Clinical Trials Research	Dana Farber/Harvard Cancer Center

Local Invited Presentations

1998 Targeted Therapies in GI Malignancies/ Grand Rounds
Department of Medicine, MGH

2001 Targeting signal transduction in cancer therapy/Grand Rounds
Department of Hematology Oncology, DF/PCCC

2002 Colorectal cancer: current concepts/Grand Rounds
Department of Hematology Oncology, Lowell General Hospital

2003 Hepatocellular cancer: current concepts/Grand Rounds

2003	Department of Hematology Oncology, Lowell General Hospital Gastric cancer: current concepts /Grand Rounds
2004	Department of Hematology Oncology, Lowell General Hospital Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Addison-Gilbert Hospital, Gloucester,
2005	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Emerson Hospital, Concord, MA
2006	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Emerson Hospital, Concord, MA
2006	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology, Lowell General Hospital
2007	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Emerson Hospital, Concord, MA
2008	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Emerson Hospital, Concord, MA
2009	Review of oncology cases and recommendations for treatment/Case Reviews Department of Hematology Oncology/ Southern New Hampshire Hospital, NH

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Regional

2003	Harvard Course Topics in Gastrointestinal Cancers
2006	Harvard Course Topics in Gastrointestinal Cancers
2007	Harvard Course Topics in Gastrointestinal Cancers

National

1985	Interleukin-2 Therapy of Melanoma and Renal Cell Cancer/ ASCO Symposium San Diego, California
2004	Pancreatic cancer: small steps forward / VICCAN Fall Scientific Meeting Stone Mountain, Georgia
2005	Developmental Therapeutics: Molecular Therapeutics/ ASCO 41 st Annual Meeting Orlando, Florida
2009	Improving Clinical Trials Systems in Cancer Research/ NCCN Conference Washington DC
2010	Improving Clinical Trials Systems in Cancer Research/ Ensemble Conference Chapel Hill
2010	Biomarkers in Angiogenesis, Joint Meeting of AACR and Metastasis Society

International

1984	HTLV-I Associated Leukemia/Lymphoma/ European Society of Medical Oncology (ESMO) Annual Meeting Nice, France
1987	New approaches utilizing Biological Response Modifiers/ Symposium on Biological Response

	Modifiers
	Amsterdam, Netherlands
1991	Targeting BFGF in treatment of melanoma/ Symposium on Angiogenesis in Cancer Granada, Spain
2005	Developmental Therapeutics: Molecular Therapeutics/ Symposium: Academic Research in Minority Populations in China Xinjiang Medical University, Xinjiang, China
2006	Asian Medical Center, Seoul, South Korea
2010	Drug Development in the Molecularly Targeted Era: An Odyssey. International Cancer Congress, Hong Kong, China

Report of Clinical Activities and Innovations

Current Licensure and Certification

1979	National Board of Medical Examiners
1981	American Board of Internal Medicine
1983	ABIM Certified in Medical Oncology
1984	Maryland License
1988	Rhode Island License
1994	Massachusetts License

Practice Activities

Outpatient Medical Oncology-approximately 22 hours per week in MGH Gosnell GI Cancer Center
Inpatient Medical Oncology-rounding on inpatients for approximately 2 hours per day.

Clinical Innovations

Report of Technological and Other Scientific Innovations

Report of Education of Patients and Service to the Community

Activities

Educational Material for Patients and the Lay Community

Educational material or curricula developed for non-professional students

Patient educational material

Assisted in development of CD on clinical trials: **Entering a clinical trial: Is it right for you?**

Recognition

Report of Scholarship

Publications

Original Articles

1. Hochman R, Clark JW, Rolla AR, Thomas S, Kaldany A, D'Elia JA. Bleeding in patients with infections: are antibiotics helping or hurting? *Arch Intern Med* 1982;142(8):1440-2.
2. Clark J, Hochman R, Rolla AR, Thomas S, Miller DG, Kaldany A, D'Elia JA. Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure. *Clin Exp Dial Apheresis* 1983;7(3):177-90.
3. Blattner WA, Gibbs WN, Saxinger C, Robert-Guroff M, Clark J, Lofters W, Hanchard B, Campbell M, Gallo RC. Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. *Lancet* 1983;2(8341):61-4.
4. Mann DL, Clark J, Clarke M, Reitz M, Popovic M, Franchini G, Trainor CD, Strong DM, Blattner WA, Gallo RC. Identification of the human T cell lymphoma virus (HTLV) in B-cell lines established from patients with adult T cell leukemia. *J Clin Invest* 1984;74(1):56-62.
5. Nowell PC, Finan JB, Clark JW, Sarin PS, Gallo RC. Karyotypic differences between primary cultures and cell lines from tumors with the human T-cell leukemia virus. *J Natl Cancer Inst* 1984;73(4):849-52.
6. Biggar RJ, Saxinger C, Gardiner C, Collins WE, Levine PH, Clark JW, Nkrumah FK, Blattner WA. Type-I HTLV antibody in urban and rural Ghana, West Africa. *Int J Cancer* 1984; 34(2):215-9.
7. Saxinger W, Blattner WA, Levine PH, Clark J, Biggar R, Hoh M, Moghissi J, Jacobs P, Wilson L, Jacobson R, Crookes R, Strong M, Ansari AA, Dean AG, Nkrumah FK, Murali N, Gallo RC. Human T-cell leukemia virus (HTLV-1) antibodies in Africa. *Science* 1984; 225:1473-6.
8. Merino F, Robert-Guroff M, Clark J, Biondo-Bracho M, Blattner WA, Gallo RC. Natural antibodies to human T-cell leukemia/lymphoma virus in healthy Venezuelan populations. *Int J Cancer* 1984;34(4):501-6.
9. Clark JW, Hahn BH, Mann DL, Wong-Staal F, Popovic M, Richardson E, Strong DM, Lofters WS, Blattner WA, Gibbs WN, Gallo RC. Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus. *Cancer* 1985;56(3):495-9.

10. Weiss SH, Goedert JJ, Sarngadharan MG, Bodner AJ, Gallo RC, Blattner WA, Biggar RJ, Clark JW, Giron A, Dodd RY, Melbye M, Masure H, Getmann EP, Lane HC, Fauci AS, Hoffaagle JH, Simberkoss M, Winn DM, Greene MH, Saxinger CW, Robert-Guroff M, Gallo RC, Blattner WA. Screening test for HTLV-III (AIDS-agent) antibodies: specificity, sensitivity, and applications. *JAMA* 1985;253:221-5.
11. Clark JW, Robert-Guroff M, Ikehara O, Henzan E, Blattner WA. Human T-cell leukemia-lymphoma virus type 1 and adult T-cell leukemia-lymphoma in Okinawa. *Cancer Res* 1985; 45(6):2849-52.
12. Clark J, Saxinger C, Gibbs WN, Lofters W, Lagrenade L, Deceulaer K, Ensroth A, Robert-Guroff M, Gallo RC, Blattner WA. Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica. *Int J Cancer* 1985;36:37-41.
13. Blattner WA, Biggar RJ, Weiss SH, Clark JW, Goedert JJ. Epidemiology of human lymphotropic retroviruses: an overview. *Cancer Res* 1985;45(9 Suppl):4598s-601s.
14. Robert-Guroff M, Clark JW. Antigenicity of human T-cell leukemia virus-associated gp52: greater response in leukemia patients compared to healthy donors exposed to the virus. *Cancer Res* 1985;45(7):3374-7.
15. Tollerud DJ, Clark JW, Brown LM, Neuland C, Mann D, Blattner WA, Hoover RN. Systemic lupus erythematosus with deficiency of the T4 epitope on T4 helper/inducer cells. *N Engl J Med* 1985;313(24):1544-5.
16. Jaffe ES, Clark J, Steis R, Blattner W, Macher AM, Longo DL, Reichert CM. Lymph node pathology of HTLV and HTLV-associated neoplasms. *Cancer Res* 1985;45(9 Suppl):4662s-4s.
17. Robert-Guroff M, Clark J, Lanier AP, Beckman G, Melbye M, Ebbesen P, Blattner WA, Gallo RC. Prevalence of HTLV-I in Arctic regions. *Int J Cancer* 1985;36(6):651-5.
18. Blattner WA, Nomura A, Clark JW, Ho GY, Nakao Y, Gallo R, Robert-Guroff M. Modes of transmission and evidence for viral latency from studies of human T-cell lymphotropic virus type I in Japanese migrant populations in Hawaii. *Proc Natl Acad Sci USA* 1986;83:4895-8.
19. Gibbs WN, Lofters WS, Campbell M, Hanchard B, LaGrenade L, Crantson B, Hendriks J, Jaffe ES, Saxinger C, Robert-Guroff M, Gallo RC, Clark J, Blattner WA. Non-Hodgkin lymphoma in Jamaica and its relation to adult T-cell leukemia-lymphoma. *Ann Intern Med* 1987;106(3):361-8.
20. Clark JW, Tucker MA, Greene MH. Clinical and laboratory observations in a lymphoma-prone family. *Cancer* 1987;60(4):864-9.
21. Bartholomew C, Saxinger WC, Clark JW, Gail M, Dudgeon A, Mahabir B, Hull-Drysdale B, Cleghorn F, Gallo RC, Blattner WA. Transmission of HTLV-I and HIV among homosexual men in Trinidad. *JAMA* 1987;257(19):2604-8.
22. Smith T, Clark JW, Popp MB. Regression of melanoma nodules in a patient treated with ranitidine. *Arch Intern Med* 1987;147(10):1815-6.
23. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, Maluish AE. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. *Blood* 1988;71(5):1304-9.

24. Steis RG, Smith JW Jr, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. *N Engl J Med* 1988;318(22):1409-13.
25. Clark JW, Gurgo C, Franchini G, Gibbs WN, Lofters W, Neuland C, Mann D, Saxinger C, Gallo RC, Blattner WA. Molecular epidemiology of HTLV-I-associated non-Hodgkin's lymphomas in Jamaica. *Cancer* 1988;61(7):1477-82.
26. Reeves WC, Saxinger C, Brenes MM, Quiroz E, Clark JW, Hoh MW, Blattner WA. Human T-cell lymphotropic virus type I (HTLV-1) seroepidemiology and risk factors in metropolitan Panama. *Am J Epidemiol* 1988;127(3):532-9.
27. Giardina SL, Young HA, Faltynek CR, Jaffe ES, Clark JW, Steis RG, Urba WJ, Mathieson BJ, Gralnick H, Lawrence J, Overton WA, Longo DL. Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alpha. *Blood* 1988;72(5):1708-16.
28. Lavu S, Clark J, Swarup R, Matsushima K, Paturu K, Moss J, Kung HF. Molecular cloning and DNA sequence analysis of the human guanine nucleotide-binding protein Go alpha. *Biochem Biophys Res Commun* 1988;150(2):811-5.
29. Newman MJ, Light BA, Weston A, Tollerud D, Clark JW, Mann DL, Blackmon JP, Harris CC. Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. *J Clin Invest* 1988;82(1):145-53.
30. Levine PH, Jaffe ES, Manns A, Murphy EL, Clark J, Blattner WA. Human T-cell lymphotropic virus type I and adult T-cell leukemia/lymphoma outside Japan and the Caribbean Basin. *Yale J Biol Med* 1988;61(3):215-22.
31. Murphy EL Jr., De Ceulaer K, Williams, W, Clark JW, Saxinger C, Gibbs WN, Blattner WA. Lack of relationship between human T-lymphotropic virus type I infection and systemic lupus erythematosus in Jamaica, West Indies. *J Acquir Immune Defic Syndr* 1988;1(1):18-22.
32. Dosik H, Denic S, Patel N, Krishnamurthy M, Levine PH, Clark JW. Adult T-cell leukemia/lymphoma in Brooklyn. *JAMA* 1988;259(15):2255-7.
33. Levine PH, Blattner WA, Clark J, Tarone R, Maloney EM, Murphy EM, Gallo RC, Robert-Guroff M, Saxinger WC. Geographic distribution of HTLV-I and identification of a new high-risk population. *Int J Cancer* 1988;42(1):7-12.
34. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA, Hoover RN. Association of cigarette smoking with decreased numbers of circulating natural killer cells. *Am Rev Respir Dis* 1989;139(1):194-8.
35. Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW Jr, Coggin DL, Longo DL. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. *Blood* 1989;73(1):38-46.
36. Urba WJ, Clark JW, Steis RG, Bookman MA, Smith JW Jr, Beckner S, Maluish AE, Rossio JL, Rager H, Ortaldo JR, Longo DL. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. *J Natl Cancer Inst* 1989;81(8):602-11.

37. Brown LM, Tollerud DJ, Pottern LM, Clark JW, Kase R, Blattner WA, Hoover, RN. Biochemical epidemiology in community-based studies: practical lessons from a study of T-cell subsets. *J Clin Epidemiol* 1989;42(6):561-8.
38. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA, Hoover RN. The effects of cigarette smoking on T-cell subsets. A population-based survey of healthy caucasians. *Am Rev Respir Dis* 1989;139(6):1446-51.
39. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Pankiw-Trost LK, Blattner WA, Hoover RN. The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. *J Clin Immunol* 1989; 9(3):214-22.
40. Clark J, Longo DL. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials. *Immunology Series* 1989;48:37-58.
41. Miller RL, Steis RG, Clark JW, Smith JW Jr, Crum E, McKnight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. *Cancer Res* 1989; 49(7):1871-6.
42. Peng Z, Calvert I, Clark J, Helman L, Kahn R, Kung HF. Molecular cloning, sequence analysis and mRNA expression of human ADP-ribosylation factor. *Biofactors* 1989;2(1):45-9.
43. Tollerud DJ, Ildstad ST, Brown LM, Clark JW, Blattner WA, Mann DL, Neuland CY, Pankiw-Trost L, Hoover RN. T-cell subsets in healthy teenagers: transition to the adult phenotype. *Clin Immunol Immunopathol* 1990;56(1):88-96.
44. Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Cummings FJ, Clark J, Browne MJ, Beitz J, et al. Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. *J Natl Cancer Inst* 1990;82(21):1710-4.
45. Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. *Cancer Res* 1990;50(1):185-92.
46. Conlon KC, Urba WJ, Smith JW Jr, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. *Cancer* 1990;65(10):2237-42.
47. Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW Jr, Clark JW, Dailey V, Del Vecchio S, Shuke N, Pinsky CM, Urba WJ, Haspel M, Parantesi P, Paris B, Longo DL, Hanna MG Jr. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. *J Clin Oncol* 1990;8:476-90.
48. VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW Jr, Clark JW, Conlon K, Stevenson HC, Urba WJ, Hartmann LC, et al. Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1990;82(3):235-8.
49. Martin A, Nerenstone S, Urba WJ, Longo DL, Lawrence JB, Clark JW, Hawkins MJ, Creekmore SP, Smith JW Jr, Steis RG. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. *J Clin Oncol* 1990;8(4):721-30.

50. Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW Jr, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J, Urba W. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. *J Natl Cancer Inst* 1990;82(8):697-703.
51. Steis RG, VanderMolen LA, Lawrence J, Sing G, Ruscetti F, Smith JW Jr, Urba WJ, Clark J, Longo DL. Erythrocytosis in hairy cell leukemia following therapy with interferon alpha. *Br J Haematol* 1990;75(1):133-5.
52. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW Jr, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, Ozols R, Stevenson H, Young R, Longo D. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. *J Clin Oncol* 1990;8(10):1618-29.
53. Posner M, Slapak CA, Browne MJ, Clark JW, Curt G, Weitberg A, Calabresi P, Cummings FJ, Wiemann M, Urba S, Robert N. A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. *Am J Clin Oncol* 1990;13(5):455-8.
54. Clark JW, Smith JW Jr, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S, Stewart M, Conlon K, SznoI M, Kremers P, Cohen P, Longo DL. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. *Cancer Res* 1990;50(22):7343-50.
55. Urba WJ, Kopp WC, Clark JW, Smith JW Jr, Steis RG, Huber C, Coggin D, Longo DL. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa. *J Clin Oncol* 1991;9(10):1831-9.
56. Smith JW Jr, Longo DL, Urba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord WG, Lawrence JB, Steis RG. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. *Blood* 1991;78(7):1664-71.
57. Smith JW Jr, Urba WJ, Clark JW, Longo DL, Farrell M, Creekmore SP, Conlon KC, Jaffe H, Steis RG. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. *J Immunother* 1991;10(5):355-62.
58. Tollerud DJ, Brown LM, Clark JW, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA. Cryopreservation and long-term liquid nitrogen storage of peripheral blood mononuclear cells for flow cytometry analysis: effects on cell subset proportions and fluorescence intensity. *J Clin Lab Anal* 1991;5(4):255-61.
59. Clark JW, Posner MR, Marsella JM, Santos A, Uskokovic M, Eil C, Lasky SR. Effects of analogs of 1,25(OH)₂ vitamin D₃ on the proliferation and differentiation of the human chronic myelogenous leukemia cell line, RWLeu-4. *J Cancer Res Clin Onc* 1992;8(3):190-4.
60. Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W. A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. *Am J Clin Oncol* 1992;15(3):239-41.
61. Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. *Cancer* 1992; 70(12):2929-34.

62. Sznol M, Clark JW, Smith JW Jr, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, Creekmore SP, Kremers P, Conlon K, Hursey J, Beveridge J, Longo DL. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. *J Natl Cancer Inst* 1992;84(12):929-37.
63. Kato J, Wanebo H, Calabresi P, Clark JW. Basic fibroblast growth factor production and growth factor receptors as potential targets for melanoma therapy. *Melanoma Res* 1992; 2(1):13-23.
64. Beitz JG, Davol P, Clark JW, Kato J, Medina M, Frackelton AR Jr, Lappi DA, Baird A, Calabresi P. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. *Cancer Res* 1992;51(1):227-30.
65. Weitberg AB, Yashar J, Glicksman AS, Posner M, Cummings F, Browne M, Clark J, Calabresi P, Beitz J, Murray C. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. *Eur J Cancer* 1993;29A(4):511 -5.
66. Posner GH, Dai H, Guyton KZ, Kensler TW, Reddy GS, Clark JW, Wankadiya KF, Tserng K-Y, Barsony J, Lieberman ME. 1-(hydroxyalkyl)-25-hydroxyvitamin D₃ analogs of calcitrol: preliminary biological evaluation. *Bioorg Med Chem Lett* 1993;3(9):1835-40.
67. Clark JW, Reddy GS, Santos-Moore A, Wankadiya KF, Reddy GP, Eil C, Lasky S. Metabolism and biological activity of 1,25(OH)₂D₂ and its metabolites in a chronic myelogenous leukemia cell line, RWLeu-4. *Bioorg Med Chem Lett* 1993;3:1873-8.
68. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton AR Jr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. *Am J Pathol* 1993;142(4):1119-30.
69. Reddy GS, Clark JW. Metabolism of 1,25(OH)₂16-ENE D₃ in kidney: influence of structural modification of D-ring on side chain metabolism. *Bioorg Med Chem Lett* 1993; 3(9):1879-84.
70. Frackelton AR Jr, Kumar PS, Kannan B, Clark JW. Tyrosine phosphorylated proteins in chronic myelogenous leukemia. *Leuk Lymphoma* 1993;11 Suppl 1:125-9
71. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. *J Clin Oncol* 1994;12(12):2682-6.
72. Briggs RC, Kao WY, Dworkin LL, Briggs JA, Dessypris EN, Clark J. Regulation and specificity of MNDA expression in monocytes, macrophages, arid leukemia/B lymphoma cell lines. *J Cell Biochem* 1994;56(4):559-67.
73. Lasky SR, Posner MR, Iwata K, Santos-Moore A, Yen A, Samuel V, Clark J, Maizel AL. Characterization of a vitamin D₃-resistant human chronic myelogenous leukemia cell line. *Blood* 1994;84(12):4283-94.
74. Glicksman AS, Slotman G, Doolittle C 3rd, Clark J, Koness J, Coachman N, Posner M, DeRosa E, Wanebo H. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. *Int J Radiat Oncol Biol Phys* 1994;30(5):1043-50.
75. Cheng JC, Frackelton AR Jr, Bearer EL, Kumar PS, Kannan B, Santos-Moore A, Rifai A, Settleman J, Clark JW. Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II

rasGAPs during myelomonocytic differentiation of human leukemic cells. *Cell Growth Differ* 1995;6(2):139-48.

76. Clark JW, Chabner BA. Suramin and prostate cancer: Where do we go from here? *J Clin Oncol* 1995;13(9):2155-7.
77. Beitz JG, Darnowski JW, Cummings FJ, Browne MJ, Clark JW, Bigley JW, Weitberg AB. Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. *Cancer Invest* 1995;13(5):464-9.
78. Wanebo HJ, Glicksman AS, Clark JW. Pancreatic cancer symposium: epidemiology, etiology, pathogenesis, and therapy. *Pancreas* 1995;10(3):217-21.
79. Wanebo HJ, Glicksman AS, Landman C, Slotman G, Doolittle C, Clark J, Koness RJ. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. *Am J Surg* 1995;170(5):512-6.
80. Clark JW, Santos-Moore A, Stevenson LE, Frackelton AR Jr. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras-signaling pathway. *Int J Cancer* 1996;65(2):186-91.
81. Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J. Phase II study of 5-fluorouracil, leucovorin and azidothymidine in patients with metastatic colorectal cancer. *J Cancer Res Clin Oncol* 1996;122(9):544-8.
82. Rifai A, Brysch W, Fadden K, Clark J, Schlingensiepen K-H. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. *Amer J Pathol* 1996;149:717-25.
83. Siu-Caldera ML, Clark JW, Santos-Moore A, Peleg S, Liu YY, Uskokovich MR, Sharma S, Reddy GS. 1alpha,25-dihydroxy-24-oxo-16-ene vitamin D₃, a metabolite of a synthetic vitamin D₃ analog, 1alpha,25-dihydroxy-16-ene vitamin D₃, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. *J Steroid Biochem Mol Biol* 1996;59(5-6):405-12.
84. Glicksman AS, Wanebo HJ, Slotman G, Liu L, Landmann C, Clark J, Zhu TC, Lohri A, Probst R. Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer. *Int J Radiat Oncol Biol Phys* 1997; 39(3):721-9.
85. Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS. Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? *Cancer J Sci Am* 1999;5(4):242-7.
86. Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. *Cancer Chemother Pharmacol* 2000;46(4):319-28.
87. Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. *Ann Oncol* 2000; 11(1): 101-3.

88. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts I, Koness RJ, Levy A. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. *Arch Surg* 2000;135(1):81-7; discussion 88.
89. Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer R, Clark JW. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. *Cancer* 2000;88(1):180-5.
90. John W, Picus J, Blanke CD, Clark JW, Shulman LN, Rowinsky EK, Thornton DE, Loehrer PJ. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. *Cancer* 2000;88(8):1807-13.
91. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent: a new measure of understanding among research subjects. *J Natl Cancer Inst* 2001;93(2):139-47.
92. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. *Clin Cancer Res* 2001;7(2):231-42.
93. Lindel K, Willett CG, Shellito PC, Ott MJ, Clark J, Grossbard M, Ryan D, Ancukiewicz M. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. *Radiother Oncol* 2001;58(1):83-7.
94. Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. *Cancer Chemo Pharmacology* 2001;48(5):347-55.
95. Sunita Rao D, Balkundi D, Uskokovic MR, Tserng K, Clark JW, Horst RL, Satyanarayana RG. Double bond in the side chain of 1 α ,25-dihydroxy-22-ene-vitamin D(3) is reduced during its metabolism: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney. *J Steroid Biochem Mol Biol* 2001;78(2):167-76.
96. McMahon PM, Halpern EF, Fernandez-del Castillo C, Clark JW, Gazelle GS. Pancreatic cancer: cost-effectiveness of imaging technologies for assessing resectability. *Radiology* 2001;221(1):93-106.
97. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. *Lancet* 2001;358(9295):1772-7.
98. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. *Cancer* 2002;94(1):97-103.
99. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. *Clin Cancer Res* 2002;8(3):691-7.
100. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. *Cancer* 2002;94(12):3186-91.
101. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JW, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPAR γ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. *Cancer J* 2002;8(5):395-9.

102. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. *J Clin Oncol* 2002;20(18):3772-84.
103. Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Eder JP, Clark JW. A phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. *Cancer* 2003;97(1):148-54.
104. Brugarolas J, Clark JW, Chabner B. Using “rationally designed drugs” rationally. *Lancet* 2003;361:1758-9.
105. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, Mitchell EP, Kardinal CG. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. *J Clin Oncol* 2003;21(15):2904-11.
106. Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. *Cancer Invest* 2003;21(4):505-11.
107. Supko JG, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. *Clin Cancer Res* 2003;9(14):5178-86.
108. Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P. A phase I trial of daily oral 4'-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. *Invest New Drugs* 2004;22(2):139-50.
109. Ryan DP, Eder JP Jr, Puchalski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko, JG, Clark JW. A phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. *Clin Cancer Res* 2004;10:2222-30.
110. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blazzkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. *Nat Med* 2004;10(2):145-7.
111. Zhu AX, Puchalski TA, Stanton VP Jr, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. *Clin Colorectal Cancer* 2004;3(4):225-34.
112. Shellito PC, Clark JW, Willett CG, Caplan AP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. *N Engl J Med* 2004;350(24):2500-9.
113. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, Zhu AX, Magee CC. Gemcitabine-associated thrombotic microangiopathy. *Cancer* 2004; 100(12):2664-70.
114. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. *Cancer* 2004;101(5):934-9.

115. Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. *Cancer Invest* 2004;22(3):353-9.
116. Roberts TG Jr, Goulart BH, Squitieri L, Stallings S, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. *JAMA* 2004;292(17):2130-40.
117. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. *Am J Clin Oncol* 2004;27(5):485-8.
118. Zhu AX, Clark JW, Willett CG. Adjuvant therapy for pancreatic cancer: an evolving paradigm. *Surg Oncol Clin N Am* 2004;13(4):605-20.
119. Willett CG, Fernandez del Castillo C, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. *Ann Surg* 2005;241(2):295-9.
120. Roberts TG, Goulart BH, Clark JW, Chabner BA. Trends in the risks and benefits to patients with cancer in Phase 1 clinical trials [letter]. *JAMA* 2005;293(7):795.
121. Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. *Pancreatology* 2005;5:67-74.
122. Hamilton AL, Eder JP, Pavlik AC, Clark JW, Liebes L, Garcia-Carbonero R, Chacoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jaquotte, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. *J Clin Oncol* 2005;23:6107-16.
123. Bendell JC, Eder JP, Clark JW, Fidias P, Lynch TJ, Seiden MV, Ryan DP. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. *Cancer* 2005;103(9):1925-31.
124. Clark JW, Eder JP, Ryan D, Lathia C, Lenz H-J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor inhibitor, BAY43-9006, in patients with advanced, refractory solid tumors. *Clin Cancer Res* 2005,11(15):5472-80.
125. Ogino S, Meyerhardt J, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib (ZD 1839, EGFR tyrosine kinase inhibitor) for advanced colorectal cancer. *Clin Cancer Res* 2005;11(18):6650-56.
126. Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. *Br J Cancer* 2005;93(1):54-9.
127. Willett CG, Boucher Y, Duda DG, diTomaso E, Munn LL, Tong RT, Koizn SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and

dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. *J Clin Oncol* 2005;23(31):8136-9.

128. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. *Oncologist* 2005;10(6):392-8.
129. Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A Phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. *Digest Dis Sci* 2005;50(12):2218-23.
130. Eder J, Ryan D, Appleman L, Zhu A, Puchlaski T, He X, Sonnichsen D, Cooper M, Wright J, Clark J, Supko J. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly twenty-four hour continuous intravenous infusion in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2006;58(1):107-16.
131. Clark JW. Rubitecan. *Expert Opin Investig Drugs* 2006;15(1):71-9.
132. McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle C, Michelini A, Fuchs C. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. *Am Journal Clin Onc* 2006;29(1):40-4.
133. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. *J Clin Oncol* 2006;24(3):401-406.
134. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? *Eur J Cancer* 2006;42(4):548-56.
135. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. *J Clin Oncol* 2006;24(12):1892-97.
136. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 2006;24(12):1898-903.
137. Kulke M, Muzikansky A, Clark J, Enzinger P, Fidias P, Kinsella K, Michelini A, Fuchs C. A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. *Cancer Investig* 2006; 24:346-50.
138. Bendell JC, Lauwers GY, Willett C, Clark JW, Warshaw AL, Wain JC, Ryan DP. Pancreatoblastoma in a teenage patient. *Clin Adv Hematol Oncol* 2006; 4(2):150-3.
139. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. *Clin Cancer Res* 2006; 12:4283-7.

140. Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. *Cancer Invest* 2006; 24(3):229-34.
141. Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. *Clin Colorectal Cancer* 2006; 6(1):59-65.
142. Kulke MH, Wu B, Ryan DP, Enzinger P, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A Phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. *Dig Dis Sci* 2006; 51(6):1033-8.
143. Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. *Clin Colorectal Cancer* 2006; 6(3):208-13.
144. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr., Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. *Cancer* 2006; 107(10):2482-89.
145. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. *Cancer Chemother Pharmacol* 2007;60(5):661-70.
146. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. *Virchows Arch* 2007; 450(5):529-537.
147. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. *Oncologist* 2007; 12(4):426-37.
148. Qiao F, Pan T, Clark JW, Mawlawi OR. Region of interest motion compensation for PET image reconstruction. *Phys Med Biol* 2007; 52(10):2675-89.
149. Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. *Cancer Chemother Pharmacol* 2007; 59(3):285-93.
150. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. *Clin Cancer Res* 2007; 13(18):5232-7.
151. Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK. Targeted therapy in rectal cancer. *Oncology* 2007;21(9):1055-65.
152. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. *J Clin Oncol* 2007; 25(30):4787-92.

153. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. *Clin Cancer Res* 2007; 13:6719-26.
154. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. *Cancer* 2008; 112:1879-91.
155. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. *J Clin Oncol.* 2009; 27:193-8.
156. Kulke MH, Hornick JL, Fraumeni C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. *Clin Cancer Res.* 2009;15:338-45.
157. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. *Clin Cancer Res.* 2009;15(1):374-81.
158. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. *Ann Oncol.* 2009;20:475-80.
159. Zhu AX, Clark JW. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. *Oncologist.* 2009;14:67-9.
160. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. *J Hematol Oncol.* 2009;16;2:13.
161. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. *J Clin Oncol.* 2009;27(18):3020-6.
162. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhvani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. *J Clin Oncol.* 2009;27:3027-35.
163. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. *Cancer Res.* 2009;69:7905-10.
164. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. *Lancet Oncol.* 2010;11:48-54.

165. Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. *Cancer Chemother Pharmacol.* 2010
166. Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. *Cancer.* 2010;116(8):1879-86.
167. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med.* 2010;2:146-58.
168. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. *Oncologist.* 2010;15(6):577-83.
169. Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK. A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. *Oncologist.* 2010
170. Eunice L. Kwak, MD, PhD Yung-Jue Bang, MD, PhD D. Ross Camidge, MD, PhD Alice T. Shaw, MD, PhD Benjamin Solomon, MBBS, PhD Robert G. Maki, MD, PhD Sai-Hong I. Ou, MD, PhD Bruce J. Dezube, MD Pasi A. Jänne, MD, PhD Daniel B. Costa, MD, PhD Marileila Varella-Garcia, PhD Woo-Ho Kim, MD Thomas J. Lynch, MD Panos Fidiias, MD Hannah Stubbs, MS Jeffrey A. Engelman, MD, PhD Lecia V. Sequist, MD, MPH WeiWei Tan, PhD Leena Gandhi, MD, PhD Mari Mino-Kenudson, MD Greg C. Wei, PhD S. Martin Shreeve, MD, PhD Mark J. Ratain, MD Jeffrey Settleman, PhD James G. Christensen, PhD Daniel A. Haber, MD, PhD Keith Wilner, PhD Ravi Salgia, MD, PhD Geoffrey I. Shapiro, MD, PhD Jeffrey W. Clark MD, A. John Iafrate, MD, PhD. Response of non-small cell lung cancers with Anaplastic Lymphoma Kinase (ALK) gene rearrangements to a targeted ALK inhibitor. *N Engl J Med.* 2010 Oct 28;363(18):1693-703.
171. James E. Butrynski, M.D., David R. D'Adamo, M.D., Ph.D., Jason L. Hornick, M.D., Ph.D., Paola S. Dal Cin, Ph.D., Cristina R. Antonescu, M.D., Suresh C. Jhanwar, Ph.D., Marc Ladanyi, M.D., Marzia Capelletti, Ph.D., Scott J. Rodig, M.D., Ph.D., Nikhil Ramaiya, M.D., Eunice L. Kwak, M.D., Jeffrey W. Clark, M.D., Keith D. Wilner, Ph.D., James G. Christensen, Ph.D., Pasi A. Jänne, M.D., Ph.D., Robert G. Maki, M.D., Ph.D., George D. Demetri, M.D., and Geoffrey I. Shapiro, M.D., Ph.D. Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor, *N Engl J Med.* 2010 28;363:1727-33
172. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. *J Thorac Oncol.* 2010 Dec;5:2044-2046.
173. Case records of the Massachusetts General Hospital: Case 3-2011: a 58-year-old woman with a mass in the liver. Cusack JC Jr, Clark JW, Curley SA, Sahani DV, Zukerberg LR. *N Engl J Med.* 2011 Jan 27;364(4):362-70.
174. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. *Oncologist.* 2011;16(3):310-8.

Peer reviewed publications in print or other media

1. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. *Semin Oncol* 1984;11(3):209-26.
2. Blattner WA, Clark JW, Gibbs WN, Jaffe ES, Robert-Guroff M, Saxinger C, Gallo RC. Human T-cell leukemia/lymphoma virus: epidemiology and relationship to human malignancy. In: Gallo RC, Essex M, Gross L, editors. *Human T-cell leukemia/lymphoma virus: The family of human T-lymphotropic retroviruses: their role in malignancies and association with AIDS*. New York: Cold Spring Harbor Laboratory; 1984. p. 267-74.
3. Robert-Guroff M, Schupbach J, Blayney DW, Kalyanaraman VS, Merino F, Sarngadharan MG, Clark JW, Saxinger C, Blattner WA, Gallo RC. Seroepidemiologic studies on human T-cell leukemia/lymphoma virus, type I. In: Gallo RC, Essex M, Gross L, editors. *Human T-cell leukemia/lymphoma virus: The family of human T-lymphotropic retroviruses: their role in malignancies and association with AIDS*. New York: Cold Spring Harbor Laboratory; 1984. p. 285-95.
4. Blattner WA, Clark JW, Gibbs WN, Williams CK, Nomura A, Mann D, Saxinger C, Robert-Guroff M, Gallo RC. HTLV: Epidemiology and relationship to disease. In: Miwa M, editor. *Human retrovirus in lymphoma/leukemia*. Tokyo: Japan Science Society Press; Netherlands: VNU Science Press; 1985. p. 93-108.
5. Clark JW, Longo DL. Biologic response modifiers. In: Wiernik PH, editor. *Mediguide to oncology*. New York: DellaCorte Publications; 1986. p. 1-10.
6. Clark JW, Blattner WA, Gallo RC. Human T-cell leukemia viruses and T-cell lymphoid malignancies. In: Petersdorf RG, Adams RD, Braunwald E, Isselbacher KJ, Martin JB, Wilson JD, editors. *Harrison's principles of internal medicine, Update VII*. New York: McGraw Hill; 1986. p. 29-48.
7. Clark JW, Longo DL. Biologic response modifiers in cancer therapy. In: Magrath I, editor. *New directions in cancer treatment*. Berlin; New York: Springer-Verlag, 1988. p. 297-316.
8. Clark JW, Longo DL. Interferons in cancer therapy. *Cancer: Prin Pract Oncol updates* 1987; 1(4):1-16.
9. Clark JW, Talmedge JE. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. *Cancer chemotherapy and Annual 9*. Amsterdam: Elsevier; 1987. p. 454-72.
10. Clark JW, Longo DL. Adoptive therapies: quo vadis? *Pathol Immunopathol Res* 1988; 7(6):442-58.
11. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. *Cancer chemotherapy and biological response modifiers Annual 10*. Amsterdam: Elsevier; 1988. p. 434-59.
12. Clark JW. Microbial agents in cancer treatment. *Current Probl Dermatol* 1989;18:277-82.
13. Steis RG, Clark J, Longo DL, Smith J, Miller R, Ruscetti F, Hursey J, Urba W. A phase Ib evaluation of recombinant human granulocyte-macrophage colony-stimulating factor. In: H. G. Beger, et al., editors. *Cancer therapy*. Berlin-Heidelberg: Verlag; 1989. p. 103-11.
14. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. *Cancer*

chemotherapy and biological response modifiers Annual 11. Amsterdam: Elsevier; 1989. p. 235-64.

15. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 12. Amsterdam: Elsevier; 1991. p. 193-212.
16. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 13. Amsterdam: Elsevier; 1992;13:175-90.
17. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 14. Amsterdam: Elsevier; 1993. p. 207-26.
18. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 15. Amsterdam: Elsevier; 1994. p. 190-212.
19. Urba WI, Fuscetti FW, Clark JW. Adult T-cell leukemia/lymphoma. In: Abeloff NM, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical oncology. Philadelphia: Churchill Livingstone; 1995. p. 2173-97.
20. Clark JW, Glicksman A, Wanebo HJ. Adjuvant and systemic therapy for pancreatic cancer. *Semin in Surg Oncol* 1995;11:149-53.
21. Clark JW, Glicksman AS, Wanebo HJ. Systemic and adjuvant therapy for patients with pancreatic carcinoma. *Cancer* 1996;78(3 Suppl):688-93.
22. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 16. Amsterdam: Elsevier; 1996. p. 239-73.
23. Clark JW. Targeted therapy. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 691-708.
24. Mustafa IA, Clark J, Khorsand J, Wanebo HJ. Gastric lymphoma. In: Wanebo HJ, editor. Surgery for gastrointestinal cancer: a multidisciplinary approach. Philadelphia: Lippincott-Raven; 1997. p. 371-9.
25. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 17. Amsterdam: Elsevier; 1997. p. 287-315.
26. Clark JW. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. *Semin Oncol* 1997;24(5 Suppl 18):S18-19-S18-24.
27. Browne MJ, Clark JW. Pyrimidine analogs. In: McDonald CJ, editor. Immunomodulatory and cytotoxic agents in dermatology. New York: Marcel Dekker; 1997. p. 21-39.
28. Clark JW. Chemotherapy for soft tissue sarcomas. *Med Health RI* 1997;80(1):37-8.
29. Clark JW. Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers Annual 18. Amsterdam: Elsevier; 1999. p. 223-38.
30. Czito BG, Willett CG, Clark JW, Fernandez Del Castillo C. Current perspectives on locally advanced pancreatic cancer. *Oncology (Huntingt)* 2000;14(11):1535-45; discussion 1546, 1549-52.
31. Clark JW. Systemic chemotherapy for metastatic colorectal cancer. Up to Date Online 11.1. 2000- (continuously updated).

32. Clark JW. Targeted therapy. In Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy; principles and practice. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p.891-910.
33. Clark JW. Systemic therapy approaches for colorectal cancer. In: Willett CG, editor. American Cancer Society atlas of clinical oncology: cancer of the lower gastrointestinal tract. Hamilton, Ontario: B.C. Decker; 2001. p. 150-69.
34. Chawla AK, Kachnic LA, Clark JW, Willett CG. Combined modality therapy for rectal and colon cancer. *Semin Oncol* 2003;30(4 Suppl 9):101-12.
35. Willett CG, Clark JW. Update on combined-modality treatment options for pancreatic cancer. *Oncology (Huntingt)* 2003;17(12 Suppl 13):29-36.
36. Clark JW. Locally advanced unresectable gastric cancer. In: Abbruzzese JL, Evans DB, Willett CG, Fenoglio-Preiser C, editors. *Gastrointestinal oncology*. New York: Oxford University Press; 2003. p. 311-5.
37. Clark JW. Pancreatic Cancer. In: Furie B, Cassileth PA, Atkins MB, Mayer RJ, editors. *Clinical hematology and oncology: presentation, diagnosis, and treatment*. Philadelphia: Churchill Livingstone; 2003. p. 908-20.
38. Clark JW, Willett CG. Chemotherapy and radiation therapy of colorectal cancer. In: Rustgi A, Crawford JM, editors. *Gastrointestinal cancers: a companion to Sleisenger and Fordtran's gastrointestinal and liver disease*. New York: Saunders; 2003. p. 453-72.
39. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 2006;3(1):24-40.
40. Clark JW. Molecular Targeted Agents. In: *Cancer Chemotherapy and Biotherapy, Fifth Edition*. Editors: Bruce A. Chabner, M.D., and Dan L. Longo, M.D..

Non-peer reviewed scientific or medical publications/materials in print or other media

1. Straus SE, Armstrong G, Seidlin M, Homeff J, Clark J, Faggioni A, Pearson G, Ablashi DV, Longo D. Acyclovir treatment of human herpes virus infections: implications for the treatment of Epstein-Barr virus (EBV)-related disorders. In: Prasad U et al., editors. *Nasopharyngeal carcinoma: current concepts*. International Symposium on Nasopharyngeal Carcinoma, September 27-29, 1982. Kuala Lumpur: University of Malaya Press; 1983. p. 423-31.
2. Clark JW, Blattner WA, Gallo RC. HTLV: Epidemiology and disease relationship. In: Aoki T, Urushizaki I, Tsubura E, editors. *Manipulation of host defence mechanisms*. Tokyo: Excerpta Medica; 1984. p. 124-36.
3. Blattner WA, Clark JW, Gibbs WN, Williams CK, Nomura A, Mann D, Saxinger C, Robert-Guroff M, Gallo RC. HTLV: epidemiology and relationship to disease. In: Miwa M, Sugano H, Sugimura T, Weiss R, editors. *Retroviruses in human lymphoma/leukemia*. Proceedings of the 15th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1984. Tokyo: Japan Scientific Societies Press; Utrecht: VNU Science Press BV; 1985. p. 93-108.

Professional educational materials or reports, in print or other media

Clinical Guidelines and Reports

Thesis

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Bonate PL, Eder JP, Soulie P, Bonnetterre J, Bonnetterre ME, Ryan DP, Clark JW, Kahatt C, Herait P, Jekunen A. Pharmacokinetics of a new antiangiogenic isocoumarin derivative, NM-3 in two oral once a day-dose schedules with escalating doses. Abstract 537. Proceedings of ASCO 2003;22:134.
2. Zhu AX, Ready NE, Clark JW, Safran H, Lynch TJ, Carminati P, Zanna C, Chabner BA, Calabresi P, Supko JG. Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Abstract 557. Proceedings of ASCO 2003;22:139.
3. Soulie P, Gamelin E, Eder JP, Bonnetterre J, Ryan DP, Clark JW, Appleman LJ, Herait P, Marsh S, Jekunen A. A dose finding study of an oral antiangiogenesis inhibitor, NM-3– safety profile and effects on surrogate markers with once-daily dosing. Abstract 777. Proceedings of ASCO 2003;22:194.
4. Morgan JA, Bukowski RM, Xiong H, Clark J, Zacharchuk C, Plazney D, Pelley R, Fuchs C. Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Abstract 788. Proceedings of ASCO 2003;22:197.
5. Appleman LJ, Ryan DP, Clark JW, Eder JP, Fishman M, Cusack JC, Fidias P, Supko JG, Esseltine D, Kashala O. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Abstract 839. Proceedings of ASCO 2003;22:209.
6. Kulke M, Bergsland E, Ryan DP, Clark JW, Enzinger PC, Michelini A, Kinsella K, Fogler W, Venook A, Fuchs C. A phase II open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Abstract 958. Proceedings of ASCO 2003;22:239.
7. Wong K-K, Eder JP, Clark J, Lenz H-J, Smith J, Lee RJ, Lathia C, Humphrey R. Final results of a study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on/1week off in patients with advanced, refractory solid tumors. Abstract 976. Proceedings of ASCO 2003;22:244.
8. Joffe S, Cook EF, Clark JW, Weeks C. Altruism among participants in cancer clinical trials. Abstract 2103.

Proceedings of ASCO 2003;22:523.

9. Abrahm JL, Billings JA, Eder JP, Seiden MV, Ryan DP, Appleman LJ, Lynch TJ, Clark JW, Zhu AX, Penson RT. Palliative care consultations for patients on phase I clinical trials. Abstract 3044. Proceedings of ASCO 2003;22:757.
10. Clark JW, Niedzwiecki D, Hollis D, Mayer R. Phase II trial of 5-fluorouracil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Abstract 3584. Proceedings of ASCO 2003;22:891.
11. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Michelini A, Vincitore M, Thomas A, Fuchs CS. Phase II study of capecitabine, oxliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Abstract 3580. Proceedings of ASCO 2004;23:265.
12. Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Abstract 4040. Proceedings of ASCO 2004;23:322.
13. Goulart BHL, Roberts TG, Clark JW. Utility and costs of surrogate endpoints (SEs) and biomarkers in phase I oncology trials. Abstract 6012. Proceedings of ASCO 2004;23:520.
14. D Nickens,¹ W Tan,¹ K Wilner,¹ DR Camidge,² G Shapiro,³ B Dezube,⁴ J Clark⁵
¹Pfizer, Inc., San Diego, CA; ²University of Colorado at Denver, School of Medicine, Denver, CO; ³Dana-Farber Cancer Institute, Boston, MA; ⁴Beth Israel Deaconess Medical Center, Boston, MA; ⁵Massachusetts General Hospital, Boston, MA, USA
A Pharmacokinetic/Pharmacodynamic Evaluation of the Concentration–QTc Relationship of Crizotinib (PF-02341066), an Anaplastic Lymphoma Kinase and c-MET/Hepatocyte Growth Factor Receptor Dual Inhibitor Administered Orally to Patients with Advanced Cancer. Proceedings of AACR, 2010
15. W. Tan, K. D. Wilner, Y. J. Bang, E. L. Kwak, R. G. Maki, D. R. Camidge, B. J. Solomon, S. H. I. Ou, R. Salgia, J. W. Clark. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. Proceedings of ASCO 2010; Abstract 3.

Narrative Report (limit to 500 words)

My clinical efforts are directed towards treating patients with gastrointestinal malignancies. From 1995-2004, I helped expand the GI Medical Oncology program at MGH from one full-time individual to a program that had five full-time physicians at the time I turned it over to Dr. Ryan. This included recruiting these physicians as well as mentoring the current leader of GI Medical Oncology at MGH, Dr. Ryan, from the initiation of his fellowship.

My research efforts have been focused on the evaluation of new agents or combinations of agents for malignancies, especially for gastrointestinal cancers with a special interest in pancreatic adenocarcinomas. I am specifically interested in approaches targeting proteins mutated or over-expressed in malignant cells, such as KRAS or growth factor receptors (e.g. EGFR, HER2). This includes early evaluation of novel agents in phase I studies as well as the integration of these agents with standard chemotherapeutic regimens. Examples of studies I have led include the CALGB FOLFOX + Trastuzumab phase II trial in colorectal cancer, the initial North American sorafenib phase I trial, and the phase I trial of crizotinib (a small molecule inhibitor of the ALK kinase which has shown significant activity against tumors harboring ALK translocations, including Non-small cell lung cancers that

have EML4-ALK translocations). I have also been interested in utilizing combined modality (surgery, radiation therapy, and chemotherapy) approaches in treating these malignancies. I have worked closely with radiation therapists and surgeons in designing and performing clinical trials evaluating new approaches aimed at enhancing therapeutic efficacy in this setting, including trials evaluating the role of antiangiogenic agents to enhance efficacy of combined chemoradiotherapy.

The other major aspect of my research efforts involves evaluation of and efforts to improve the performance of clinical trials in oncology. In addition to continuous reassessment of systems issues in performance of trials, this also involves evaluation of the informed consent process and ways in which this might be improved to be most useful for individuals participating in clinical trials. As part of these responsibilities, I am in charge of the performance of the clinical trial infrastructure of the Dana Farber Harvard Cancer Center.

My teaching efforts are primarily directed at training of Hematology/Oncology fellows, especially in aspects of the diagnosis and care of patients with gastrointestinal malignancies as well as issues related to enrollment of patients on clinical trials. In the latter regard, I lecture in the “Design and Conduct of Clinical Trials” course for fellows and junior faculty and am also directed the development of the curriculum for ongoing education of fellows and faculty in issues related to the performance of clinical trials in oncology. I also attend on the Medical Oncology service at MGH one month each year and am involved in education of medical students and residents. Residents and medical students also rotate through outpatient clinics where education occurs in the direct management of patients.